Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released on January 21, 2026, the New Brunswick-based titan signaled a definitive pivot toward high-growth markets in oncology and cardiovascular technology. Despite
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its transition into a pure-play healthcare giant, the company has emerged with a leaner, more aggressive growth profile. Analysts
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ: MDT) (Medtronic), the world’s largest medical technology company. The investment closed immediately following Anteris’ underwritten offering of common stock, for a combined $320 million in gross proceeds, which supports execution of the global pivotal PARADIGM trial and advances the Company toward global commercialization of the DurAVR® Transcatheter Heart Valve (THV).
NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the pharmaceutical industry’s most feared obstacle: the "patent cliff." Following a "catapult year" in 2025, the healthcare giant is projecting
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an adjusted earnings per share (EPS) of $1.50—narrowly edging out the $1.49 consensus estimate—the medical device giant’
As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On the eve of its official fourth-quarter and full-year 2025 earnings release scheduled for January 21, 2026, the company has already signaled
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a strategic pivot toward high-growth technology. Morgan Stanley (NYSE: MS) recently released a bullish outlook for the year, projecting a
MARLBOROUGH, MA – In a move that has sent shockwaves through the medical device sector, Boston Scientific Corporation (NYSE:BSX) announced today, January 15, 2026, a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for approximately $14.5 billion. The blockbuster deal, the largest in the industry since the early 2020s,
Date: January 14, 2026 Introduction Since its high-profile separation from industrial conglomerate 3M Company (NYSE: MMM) in April 2024, Solventum Corporation (NYSE: SOLV) has undergone a profound transformation. Once a steady but overshadowed healthcare division, Solventum has emerged as a focused, multi-billion-dollar medtech powerhouse. As of early 2026, the company is in the spotlight for [...]
As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New J&J" has emerged from the 2023 spin-off of its consumer health division, Kenvue, as a lean, high-margin healthcare powerhouse. Today, the company is [...]
As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has been defined by the explosive rise of GLP-1 weight-loss drugs and the volatility of post-pandemic earnings, Abbott has successfully completed a pivot that many [...]
Date: January 9, 2026 Introduction As the global healthcare landscape undergoes a seismic shift toward personalized medicine and AI-integrated care, Medtronic plc (NYSE: MDT) stands at a critical juncture. Once viewed as a reliable but sluggish dividend aristocrat, the world’s largest standalone medical technology firm has spent the last 24 months aggressively shedding its "legacy" [...]
Today’s Date: January 9, 2026 Introduction In the rapidly evolving landscape of medical technology, few companies have managed to fundamentally reshape a multi-decade standard of care as successfully as Insulet Corporation (NASDAQ: PODD). Historically, insulin delivery was synonymous with either multiple daily injections (MDI) or cumbersome, tubed mechanical pumps. Insulet disrupted this paradigm with the [...]
The boundary between human intent and digital action has reached a historic tipping point. As of early 2026, the integration of advanced artificial intelligence into Brain-Computer Interfaces (BCIs) has transformed what was once a slow, stuttering communication method for the paralyzed into a fluid, near-natural experience. By leveraging Transformer-based foundation models—the same architecture that powered [...]
